https://gefitinib-basedprotac3.....com/role-associated
Patients and practices We retrospectively collected the health data of thirty-two patients with advanced/metastatic STS just who obtained chemotherapy combined with anlotinib plus anlotinib maintenance treatment. The target reaction rate (ORR) and condition control rate (DCR) were calculated according to the RECIST 1.1 requirements. The progression-free prices (PFRs) at three and half a year, the progression-free survival (PFS) time, and damaging occasions had been recorded. Res
Like
Comment
Share
